Adult haemophilia A patients with inhibitors: Successful immune tolerance induction with a single FVIII/VWF product

Haemophilia

Volumn 20, Issue 6, 2014, Pages e414-e417

  Rangarajan, Savita ^a,b   Jimenez Yuste V ^c   Santagostino, E ^d  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; DRUG COMBINATION; FACTOR VIII, VON WILLEBRAND FACTOR DRUG COMBINATION; VON WILLEBRAND FACTOR;

ADULT; AGED; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; ITALY; LETTER; MIDDLE AGED; MULTICENTER STUDY; PLEURA DISEASE; PLEURAL HEMORRHAGE; PRIORITY JOURNAL; RESPIRATORY TRACT HEMORRHAGE; SPAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM; YOUNG ADULT; BLOOD; DRUG COMBINATION; IMMUNOLOGY; MALE;

ADULT; BLOOD COAGULATION FACTOR INHIBITORS; DRUG COMBINATIONS; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; MALE; VON WILLEBRAND FACTOR;

EID: 84925954257     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12521     Document Type: Letter

References (10)

1. Philipp C. The aging patient with hemophilia: complications, comorbidities, and management issues. Hematology Am Soc Hematol Educ Program 2010; 2010: 191-6.
2. Fransen van de Putte DE, Fischer K, Makris M et al. Increased prevalence of hypertension in haemophilia patients. Thromb Haemost 2012; 108: 750-5.
3. Kamphuisen PW, ten Cate H. Cardiovascular risk in patients with hemophilia. Blood 2014; 123: 1297-301.
4. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
5. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600-3.
6. van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89: 475-9.
7. Kurth M, Puetz J, Kouides P et al. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. J Thromb Haemost 2011; 9: 2229-34.
8. Oldenburg J, Jimenez-Yuste V, Peiro-Jordan R, Aledort LM, Santagostino E. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate. Haemophilia 2014; 20: 83-91.
9. Rangajaran S, Yee TT, Roy A. Immune tolerance induction in adult severe haemophilia A patients with a single FVIII/VWF product: the UK experience. J Thromb Haemost 2013; 11(Suppl 2): 1081.
10. Gringeri A, Musso R, Bernasconi S et al. Immune tolerance induction (ITI) with a high purity VWF concentrates in inhibitor patients with a high risk of a poor response to ITI: a prospective surveillance. J Thromb Haemost 2005; 3(Suppl 1): A207.